HEALTHCARE ROYALTY - Key Persons
Aaron B. Simon is an Analyst at HCRx. Mr. Simon supports HCRx's transaction-related activities, including financial analysis, transaction structuring and due diligence. Mr. Simon also participates in HCRx's business development activities. Prior to joining HCRx, Mr. Simon worked on the healthcare investment banking team at Citigroup, where he advised on both M&A and capital raising activities for companies across Biopharma, MedTech and Healthcare Services. Mr. Simon holds a B.A., cum laude, in Economics from Harvard College.
Job Titles:
- Controller
- Senior Vice President
- Senior Vice President and Controller at HCRx
Amy Zacharias is a Senior Vice President and Controller at HCRx. Ms. Zacharias is responsible for all accounting related matters concerning HCRx funds including monthly reporting, financial statements, carried interest calculations, audits and tax. She also oversees the relationship between HCRx and its fund administrator.
Prior to joining HCRx, Ms. Zacharias served as an Assurance Associate in the Financial Services Group at RSM US LLP, where she was responsible for conducting risk analysis and audits for private equity funds, fund-of-funds and hedge funds. She previously served in the Federal Tax Department at IBM. Ms. Zacharias holds a B.B.A. in Public Accounting from Pace University.
Job Titles:
- Vice President
- Vice President at HCRx
Andrew Logerfo is a Vice President at HCRx. Mr. Logerfo supports HCRx's transaction-related activities, including financial analysis, transaction structuring and due diligence. Mr. Logerfo also participates in HCRx's business development activities. Prior to joining HCRx full-time, Mr. Logerfo was a summer associate in 2022. Previously, Mr. Logerfo worked at BMO Capital Markets in its healthcare investment banking group, where he focused on M&A and capital raising activities for biopharma companies. Mr. Logerfo holds an MBA from Columbia Business School and a B.A. in Government from Georgetown University.
Job Titles:
- Chief Investment Officer for the Maryland State Retirement
- Member of the Board of Managers of HCRx Holdings
Andrew Palmer has served as a member of the Board of Managers of HCRx Holdings since May 2023. Mr. Palmer is the Chief Investment Officer for the Maryland State Retirement and Pension System. In this role, he is responsible for the day-to-day operations of the System's investment division and has overall responsibility for the System's investment program. Previously he was the Deputy Chief Investment Officer, Director of Fixed Income for the Tennessee Consolidated Retirement System. In addition to his role as Director of Fixed Income, he led the construction of a Strategic Lending Portfolio, was a member of the Private Equity and Real Estate Committees and shared in the responsibility for tactical asset allocation and new product development. He began his career at ASB Capital Management, a Bethesda, Maryland based institutional advisory firm. Mr. Palmer is a member of the ILPA, has been active in the CFA program and was President of the Washington Association of Money Managers. He received a B.A. and a M.A. in Economics from the University of Maryland.
Job Titles:
- Senior Managing Director
- Senior Managing Director at HCRx
Anthony G. Rapsomanikis is a Senior Managing Director at HCRx. Mr. Rapsomanikis opened HCRx's San Francisco office in 2015, and is now focused primarily on HCRx's activities in the mid-Atlantic region, including the greater NY metropolitan area, where he is responsible for transaction sourcing and structuring. Since joining HCR in 2012, Mr. Rapsomanikis has worked on investments representing over $1.6 billion in transaction value. Prior to joining HCRx, Mr. Rapsomanikis worked as an analyst in the healthcare investment banking group at Stifel Nicolaus Weisel and its predecessor firm Thomas Weisel Partners, where he was focused on mergers and acquisitions, and debt and equity financings. Prior to Stifel, Mr. Rapsomanikis was an analyst at Silverwood Partners. Mr. Rapsomanikis currently serves as a member of the Board of Directors of Valinor Pharmaceuticals. Mr. Rapsomanikis holds a B.B.A., cum laude, from the University of Massachusetts, Amherst.
Job Titles:
- Chief Business Officer
- Chief Business Officer at HCRx
Carlos M. Almodóvar is the Chief Business Officer at HCRx. Mr. Almodóvar leads HCRx's fundraising efforts and assists in other strategic Firm initiatives. Prior to joining HCRx, Mr. Almodóvar was director, business development at Strategic Value Partners, an alternative investment firm focused on distressed debt. Previously, Mr. Almodóvar served as an associate director at UBS where he focused on raising capital for external private fund managers. Mr. Almodóvar began his career as an analyst in the real estate investment banking group at Lehman Brothers. Mr. Almodóvar holds a B.S. from Cornell University.
Job Titles:
- Chief Financial Officer
- President
- Member of the Board of Managers of HCRx Holdings
- President, Chief Financial Officer and a Member
Christopher A. White has served as a member of the Board of Managers of HCRx Holdings since October 2022. Mr. White is President, Chief Financial Officer and a member of the Investment Committee at HCRx. Mr. White rejoined the Investment Committee in 2015, having previously served on HCRx's Investment Committee as a Cowen, Inc. representative from HCRx's inception through 2011. Mr. White is responsible for administration of the Firm's origination and sourcing function, and for strategic and operational aspects of HCRx's business in addition to his duties on the Investment Committee. He has over thirty years of legal, financial and operational experience. He previously served as managing director and head of investment banking at Janney Montgomery Scott. Prior to that position, Mr. White spent over a decade at Cowen where he held a number of senior management positions. He previously served in senior leadership positions at Salomon Smith Barney and as a securities and mergers & acquisitions lawyer. Mr. White holds a B.A. from Amherst College and a J.D. from the University of Michigan Law School.
Job Titles:
- Chairman
- Chief Executive Officer
- Chairman and Chief Executive Officer of HCRx
- Chairman of the Board of Managers of HCRx Holdings
Clarke B. Futch has served as Chairman of the Board of Managers of HCRx Holdings since October 2022. Mr. Futch is Chairman and Chief Executive Officer of HCRx. He is responsible for all of HCRx's business activities, sets the strategic direction of the firm and remains actively involved in new opportunities. Mr. Futch is considered an early pioneer in the royalty space, having been named in 2010 one of the future leaders in biotech finance by BioWorld, a leading industry publication. Since 2001, he has led/co-led 60+ royalty-related acquisitions with an aggregate value of nearly $4 billion. Mr. Futch brings over 30 years of experience in biopharmaceutical/healthcare investing and financing, having raised over $8 billion in equity and debt principal capital across eleven vehicles and executed more than 165 transactions, including royalty, equity, debt and M&A financings. Before co-founding HCRx, Mr. Futch served as a partner at Paul Capital Partners where he co-managed the firm's royalty activities as a member of the royalty management committee. Previously, he served as a founding member of the healthcare group at Thomas Weisel Partners (now Stifel), and as a vice president at Raymond James. Mr. Futch is Chairman of the Board of Directors of Valinor Pharmaceuticals. Mr. Futch holds a B.A., magna cum laude, from Vanderbilt University and a J.D. from the University of Virginia School of Law.
Job Titles:
- Vice President
- Vice President at HCRx
Collin G. Stewart is a Vice President at HCRx. Mr. Stewart supports HCRx's transaction-related activities, including financial analysis, transaction structuring and due diligence. Mr. Stewart also participates in HCRx's business development activities. Prior to joining HCRx, Mr. Stewart worked at Mizuho Securities in its healthcare investment banking group, where he focused on M&A and capital raising activities for biopharma companies. Mr. Stewart holds a B.S. in Business Administration with a concentration in Finance from The Ohio State University.
Job Titles:
- Head of Public Markets
- Member of the Board of Managers of HCRx Holdings
Craig Heron has served as a member of the Board of Managers of HCRx Holdings since October 2022. Mr. Heron is Head of Public Markets and the fund manager for Railpen's range of multi and single asset public market pooled funds, including the Growth Fund. Mr. Heron joined Railpen in September 2011 and has 26 years' investment experience. Before joining Railpen, Mr. Heron held a position as a multi-asset manager, responsible for a range of portfolios and regional funds at Henderson Global Investors and New Star Asset Management. Mr. Heron holds a Bachelor's degree in Actuarial Mathematics and Statistics from Heriot-Watt University, and is a CFA charterholder.
Job Titles:
- Senior Associate
- Senior Associate at HCRx
Evan Bograd is a Senior Associate at HCRx. Mr. Bograd supports HCRx's transaction-related activities, including financial analysis, transaction structuring and due diligence. Mr. Bograd also participates in HCRx's business development activities. Prior to joining HCRx, Mr. Bograd worked in the healthcare investment banking practices of Bank of America and Mizuho, where he focused on M&A and capital raising activities for biopharma companies. Mr. Bograd holds a B.A. in Economics from Pomona College.
Frank M. Armstrong, M.D. has been a member of HCRx's SAB since 2009. Dr. Armstrong is particularly helpful to HCRx in its medical assessment of product candidates and clinical data. Over the course of his tenured career, Dr. Armstrong has served as chief executive officer at a number of healthcare and biopharmaceutical companies, including Fulcrum Pharma, CuraGen Corporation, Bioaccelerate Holdings, Provensis and Phoqus Pharmaceuticals. Dr. Armstrong has also worked in large pharma as head of worldwide product development at Bayer AG, a senior vice president at Zeneca Pharmaceuticals (now AstraZeneca plc) and a senior vice president at Merck Serono. Dr. Armstrong holds an MBChB from the University of Edinburgh and is a Fellow of the Royal College of Physicians, Edinburgh and the Faculty of Pharmaceutical Physicians. He serves as a non-executive Chair for Faron Pharmaceuticals, a publicly held company, as well as BioCaptiva, Bloomsbury Genetic Therapies (BGT), Newcells Biotech, all privately-held companies, and is a board member for ECO Animal Health a public company. Dr. Armstrong is also a Member of the Court of the University of Edinburgh.
Gary A. Lyons has been a member of HCRx's SAB since 2018. HCRx utilizes Mr. Lyons' decades-long experience as a CEO and senior manager in the biopharmaceutical sector to evaluate potential products of interest particularly on the West Coast. Mr. Lyons has more than 40 years of industry experience, including as Chief Executive Officer of Neurocrine Biosciences, Inc., a position he held from 1993 through 2008. Mr. Lyons remains on the Board of Directors of Neurocrine. Prior to Neurocrine, Mr. Lyons held several senior management positions at Genentech, including Vice President of Business Development and Vice President of Sales. While at Genentech, Mr. Lyons also served as a member of the company's Executive Committee and was responsible for international licensing, acquisitions and partnering for Genentech's Corporate Venture Program. Mr. Lyons currently serves on the Board of Directors of Rigel, Inc and is the Chairman of the Board of Directors of Travere Therapeutics. He holds a B.S. in Marine Biology from the University of New Hampshire and an M.B.A. from the Kellogg School of Management at Northwestern University.
Gregory B. Brown, M.D. is a co-founder of HCRx. Currently CEO of Memgen, a biotechnology company, Dr. Brown remains a member of the Firm's SAB. Dr. Brown focuses his efforts for HCRx on review of promising therapeutic categories and products. Educated as a transplantation immunologist and trained as a thoracic and vascular surgeon, Dr. Brown practiced thoracic and vascular surgery in a community setting where he also founded and led an HMO. He brings particular expertise in the scientific, technical, clinical and medical evaluation of products as well as in healthcare systems and payor / reimbursement dynamics. He has been involved in sourcing, diligencing and closing more than $1 billion of royalty investments. Before co-founding HCRx, Dr. Brown was a partner at Paul Capital Partners, where he co-managed that firm's royalty investments as a member of the royalty management committee. Prior to beginning his principal investment career in 2003, Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International. Dr. Brown holds a B.A. from Yale, an M.D. from SUNY Upstate Medical Center and an M.B.A. from Harvard Business School. He currently serves as an outside director on the boards of Aquestive Therapeutics and Lisata Therapeutics.
Hayden C.B. Futch is an Analyst at HCRx. Mr. Futch supports HCRx's strategic and business development activities. Mr. Futch holds a B.A. in Mathematics and Computer Science from Vanderbilt University.
Job Titles:
- Senior Managing Director
- Senior Managing Director and Member of the Investment Committee at HCRx
John A. Urquhart is a Senior Managing Director and member of the Investment Committee at HCRx. Mr. Urquhart, based in Boston, is focused primarily on HCRx's activities in New England, including transaction sourcing and structuring. Mr. Urquhart has over a decade of healthcare investing experience in the royalty and debt markets. Since 2012, he has worked on twenty-one investments representing $1.3 billion in transaction value, including as the lead on thirteen of these investments, representing commitments in excess of $1 billion. Prior to joining HCRx in 2007 as HCR's first employee, Mr. Urquhart was an investment banking analyst at Cowen and Company, where he focused on mergers and acquisitions as well as debt and equity financings. Mr. Urquhart holds a B.A. from Brown University and an M.B.A. from The Wharton School of the University of Pennsylvania.
Job Titles:
- Managing Director
- Managing Director at HCRx
Joshua C. House is a Managing Director at HCRx. Mr. House, based in San Francisco, is focused primarily on HCRx's activities on the west coast, including transaction sourcing and structuring. Prior to joining HCRx, Mr. House was Chief Financial Officer of Hummingbird Bioscience, a clinical-stage antibody platform company focused on oncology and autoimmune disease. Prior to joining Hummingbird, Mr. House held business development roles at Consonance-HFW Acquisition Corp. and Atara Biotherapeutics, and was an investment banking Vice President at Citigroup where he covered west coast-based life sciences companies. During his career in the life sciences industry he has executed equity, M&A and licensing transactions representing over $4 billion in transaction value. Mr. House holds a B.A. from Stanford University and J.D. and M.B.A. degrees from Columbia University.
Julie H. McHugh has been a member of HCRx's SAB since 2016. HCRx utilizes Ms. McHugh's experience commercializing products and operating businesses when reviewing potential investments. Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, from March 2010 through May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Previously, Ms. McHugh was the chief executive officer of Nora Therapeutics, a biotech start-up company focused on developing novel therapies for the treatment of infertility disorders. Before that she served as company group chairman for Johnson & Johnson's (J&J) worldwide virology business unit, and as president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh oversaw the development and launches of several products, including Remicade® (infliximab), Prezista® (darunavir) and Intelence® (etravirine), and she was responsible for oversight of a research and development portfolio including compounds for HIV, hepatitis C and tuberculosis. Prior to joining Centocor, Ms. McHugh led the marketing communications for gastrointestinal drug Prilosec® (omeprazole) at Astra-Merck Inc. Ms. McHugh is an outside board member of Ironwood Pharmaceuticals, Lantheus Medical Imaging and Trevena, all publicly held companies, and The New Xellia Group, a privately held company. She currently serves on the board of visitors for the Smeal College of Business of the Pennsylvania State University. Ms. McHugh previously served on the board of directors for Aerie Pharmaceuticals, Evelo Biosciences, Trevena Pharmaceuticals, ViroPharma, Epirus Biopharmaceuticals, the Biotechnology Industry Organization (BIO), the Pennsylvania Biotechnology Association and the New England Healthcare Institute (NEHI). Ms. McHugh received her M.B.A. from St. Joseph's University and her B.S. from Pennsylvania State University.
Job Titles:
- Managing Director and Head of Business Governance and Portfolio Oversight at TD Asset Management
- Member of the Board of Managers of HCRx Holdings
Julie Sherratt has served as a member of the Board of Managers of HCRx Holdings since June 2024. Ms. Sherratt is a Managing Director and Head of Business Governance and Portfolio Oversight at TD Asset Management, where she is responsible for risk analytics, monitoring and performance oversight of all investment strategies, including fixed income, equity, quantitative and synthetic mandates, managed by the firm. She also oversees TD Asset Management's regulatory governance and operational risk management. Ms. Sherratt was formerly Vice President at TD Harbour Capital, where she handled client service, trading and operations for high-net-worth clients. Ms. Sherratt holds a B.A. in Economics from Simon Fraser University.
Job Titles:
- Executive Assistant
- Executive Assistant at HCRx
Lauren C. Jorgensen is an Executive Assistant at HCRx. Ms. Jorgensen supports, among others, HCRx's investment and legal teams.
Prior to joining HCRx as an Administrative Assistant in 2013, Ms. Jorgensen worked at the Side by Side Charter School as a teaching assistant. Ms. Jorgensen holds a MAT from Sacred Heart University and a B.S. from Western Connecticut State University, School of Professional Studies.
Job Titles:
- Senior Associate
- Senior Associate at HCRx
Lauren Janulewicz, Ph.D. is a Senior Associate at HCRx. Dr. Janulewicz primarily supports HCRx's research efforts. Dr. Janulewicz also participates in HCRx's business development and transaction-related activities, including financial analysis, transaction structuring and due diligence. Dr. Janulewicz holds a Ph.D. in Molecular Biophysics from New York University, where she developed a life science tool used to discover druggable sites on an oncogene present in up to 20% of human cancer. Prior to that, Dr. Janulewicz received her M.Phil from NYU and a B.Sc. in Biochemistry and Molecular Biology from the University of Georgia.
Job Titles:
- Member of the Board of Managers of HCRx Holdings
Marc D. Kozin has served as a member of the Board of Managers of HCRx Holdings since October 2022. Previously, Mr. Kozin served as Chairman of HCRx's Senior Advisors Board and has been a Senior Advisor since 2013. He is also a senior advisor and former president of L.E.K. Consulting, a global management consulting firm. Mr. Kozin has three decades of global experience in strategy consulting and mergers and acquisition management. He also has substantial industry expertise advising biopharmaceutical, life sciences and medtech companies. During his tenure at L.E.K., Mr. Kozin advised senior executives in life sciences to help them identify new growth opportunities, build value, pursue highly-profitable mergers and acquisitions, and support sustained growth. He helped open that firm's Boston office in 1987 and oversaw the growth of the firm's U.S. operations including the company's acquisition of shareholder value consulting firm Alcar in 1993. In 2002, Consulting Magazine named Mr. Kozin one of the 25 most influential consultants in recognition of his leadership and results for clients. He holds a B.A., magna cum laude, from Duke University, and an M.B.A. with distinction from The Wharton School at the University of Pennsylvania. Mr. Kozin currently serves as an outside board director of Dicerna Pharmaceuticals, Endocyte, UFP Technologies, OvaScience, Flex Pharma and VBL Therapeutics, all publicly held companies, and Frequency Tx, a privately held company.
Job Titles:
- Member of the Board of Managers of HCRx Holdings
Mardi C. Dier has served as a member of the Board of Managers of HCRx Holdings since October 2022. Ms. Dier most recently served as Chief Financial Officer and Chief Business Development Officer of ACELYRIN, INC. Prior to ACELYRIN, she served as Chief Financial Officer of Ultragenyx. Ms. Dier also served as Executive Vice President and Chief Financial Officer, and also as Chief Business Officer, of Portola Pharmaceuticals, Inc., a biopharmaceutical company, from November 2013 and October 2018, respectively, until its acquisition by Alexion Pharmaceuticals in July 2020, and as a Senior Vice President and Chief Financial Officer from August 2006 to November 2013. From 2003 to 2006, Ms. Dier served as Vice President of Investor Relations at Chiron Corporation, a biopharmaceutical company. From 1994 to 2001, Ms. Dier served as a Director, Investment Banking at Prudential Securities, Inc., a securities firm. Ms. Dier previously served as a supervising senior accountant at the audit department of KPMG Peat Marwick, an accounting firm, from 1986 to 1990. Ms. Dier currently serves as a director of Prelude Therapeutics and a director and member of the audit committee of Oric Pharmaceuticals, Inc. and Synthekine. Ms. Dier holds a B.S. in Biology from Stanford University and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.
Job Titles:
- Senior Vice President
- Senior Vice President at HCRx
Michele D. Romaniello is a Senior Vice President at HCRx. Ms. Romaniello manages the day-to-day operations of the HCRx office as well as HCRx's administrative team. Ms. Romaniello also supports many of the firm's core functions including marketing, business development and investor relations.
Prior to joining HCR in 2007, Ms. Romaniello was a project manager for several companies in the software development space.
Job Titles:
- Member of the Board of Managers of HCRx Holdings
Neil F. McFarlane has served as a member of the Board of Managers of HCRx Holdings since January 2024. Mr. McFarlane is the President, Chief Executive Officer and member of the board of directors of Zevra Therapeutics. He previously served as the Chief Executive Officer and a member of the Board of Directors for Adamas Pharmaceuticals until November 2021, when Adamas was acquired by Supernus Pharmaceuticals. Prior to Adamas, Mr. McFarlane served as the Chief Operating Officer of Retrophin (now Travere Therapeutics). Prior to his position at Retrophin, Mr. McFarlane held positions of increasing responsibility with UCB, Genzyme (now Sanofi) and Sangstat Medical (acquired by Genzyme). Mr. McFarlane currently serves on the Board of Directors for Collegium Pharmaceuticals. He proudly served as an officer and enlisted soldier in the United States Army Reserves, and earned his B.S. and M.S. in Nursing from the University of Florida.
Job Titles:
- Clerk
- Finance
- Member of the Finance Team
Rosa I. Mercado is a member of the Finance team where she is responsible for a number of critical tasks, including accounts payable, expense tracking and other financial reporting. Ms. Mercado also supports other finance team members and is responsible for managing HCRx's investor events.
Prior to joining HCRx in 2010, Ms. Mercado worked at Andriopoulos Design Associates supporting the operations and design teams.
Sean M. McMerriman is a Fund Accountant at HCRx. Mr. McMerriman supports HCRx's finance and accounting team. Prior to joining HCRx, Mr. McMerriman served as a Senior Fund Accountant at Littlejohn & Co., where he was responsible for all accounting related matters for select private equity and distressed funds. Previously he served as a Senior Assurance Associate in the Asset and Wealth Management group at PricewaterhouseCoopers LLP. Mr. McMerriman holds a B.S., magna cum laude, in Accounting and Finance from Fairfield University.
Job Titles:
- Chief Scientific Officer
- Chief Scientific Officer and Head of Research at HCRx
Shin W. Kang, Ph.D. is the Chief Scientific Officer and Head of Research at HCRx. Dr. Kang leads HCRx's research efforts as well as sourcing related to universities, research institutions and inventors. Since Dr. Kang's arrival in 2015, he has successfully integrated HCRx's research efforts into both the investment and business development processes. Prior to joining HCRx, Dr. Kang served as a vice president of equity research at Wells Fargo Securities covering the biotechnology sector. Previously, Dr. Kang managed technology, intellectual property and business development at the Mount Sinai School of Medicine. He holds a Ph.D. in Biological Chemistry/Immunology from the University of California, Los Angeles, an M.B.A. from Columbia Business School and a B.S. from the University of California, Davis. Dr. Kang also conducted research at Genentech as a postdoctoral fellow.
Job Titles:
- Chief Compliance Officer
- Counsel
- Chief Compliance Officer and Chief Patent Counsel
Spencer H. Schneider is the Chief Compliance Officer and Chief Patent Counsel at HCRx. Mr. Schneider established HCRx's compliance program, handled all aspects of the Firm's registration as an investment adviser with the SEC and manages all compliance functions. In addition, he functions as part of the transaction team, handling all investment-related intellectual property matters, throughout the investment and post-investment process. He is a registered patent attorney with extensive experience in conducting intellectual property due diligence for corporate transactions. Prior to joining HCRx, Mr. Schneider was a principal at Speyside Capital Advisors, a boutique advisory firm helping to facilitate commercialization of university inventions. Previously, Mr. Schneider was a senior lawyer in the intellectual property groups of Dewey & LeBoeuf, Ropes & Gray, and Cooper & Dunham. He has conducted patent due diligence for multiple types of transactions including public offerings, venture capital financings, mergers and acquisitions, leveraged buyouts, and royalty transactions. Mr. Schneider holds a B.A. in Biology from Columbia College, a M.S. in Biochemistry and Molecular Biology from New York Medical College, and a J.D. from Cardozo School of Law.
Job Titles:
- Executive Assistant
- Executive Assistant at HCRx
Stephanie Gilbey is an Executive Assistant at HCRx. Ms. Gilbey supports, among others, HCRx's investor relations and operations teams.
Prior to joining HCRx, Ms. Gilbey held administrative positions at Westport Energy Holdings and Citigroup. Ms. Gilbey holds an A.S. in Information Processing from Sacred Heart University.
Tatiana R. Fabian is an Analyst at HCRx. Ms. Fabian supports HCRx's transaction-related activities, including financial analysis, transaction structuring and due diligence. Ms. Fabian also participates in HCRx business development activities.
Ms. Fabian holds a B.S.B.A. and an M.S. in Finance from the University of Florida.
Job Titles:
- Chief Accounting Officer
- Treasurer
- Chief Accounting Officer and Treasurer at HCRx
Thomas K. Conner is the Chief Accounting Officer and Treasurer at HCRx. Mr. Conner oversees all of HCRx's accounting and finance related matters; including monthly reporting, financial statement preparation, tax preparation and cash management. Prior to joining HCRx, Mr. Conner was the chief operating officer of investment banking at Cowen & Company. Mr. Conner spent more than twenty years with Cowen & Company, serving as chief financial officer until its merger with Ramius. He began his career at Deloitte Haskins & Sells in 1983. Mr. Conner holds a B.B.A. from the University of Massachusetts, Amherst and is a Certified Public Accountant licensed in the State of New York.
Job Titles:
- General Counsel
- General Counsel of HCRx
Timothy R.M. Bryant is the General Counsel of HCRx. Mr. Bryant is responsible for all of HCRx's legal matters. He brings over 35 years of experience in private and public investing, having first represented biopharmaceutical royalty investors in 2001. Mr. Bryant was previously a Partner and the General Counsel of Adams Street Partners, the global private equity firm, and prior to that a Partner at McDermott Will & Emery. Mr. Bryant currently serves as a member of the Board of Directors of Valinor Pharmaceuticals. Mr. Bryant holds a B.A., M.A., and J.D., all from Northwestern University.
Job Titles:
- Associate
- Associate at HCRx
Tolly Flinn is an Associate at HCRx. Ms. Flinn supports HCRx's strategic and business development activities. Prior to joining HCRx, Ms. Flinn worked in investment banking at Centerview Partners, where she focused on M&A and strategic advisory assignments for companies across industries. Ms. Flinn holds a B.A. in Economic and Social History from Barnard College, Columbia University.
Job Titles:
- MFPM Chief Medical Officer
- MFPM Senior Advisor Board Chairman
Warren D. Cooper, MB, BS, BSc, MFPM is the Chief Medical Officer, Head of the Portfolio Management Committee and Chairman of the Senior Advisor Board at HCRx. HCRx draws extensively on Dr. Cooper's four decades of clinical, regulatory and operational expertise as it evaluates new investment opportunities. Dr. Cooper previously served as an advisor to HCRx and has been well known to the Firm since its inception having worked on numerous projects with HCRx. Dr. Cooper is a UK-trained physician with over 40 years of experience in the global pharmaceutical industry. With a background in cardiology and cardiac surgery, he spent 12 years with Merck in various positions, ultimately becoming the head of worldwide clinical research operations for Merck Research Laboratories across all therapeutic areas. Moving to AstraMerck (now AstraZeneca PLC), he led that company's cardiovascular business division, with responsibility for all aspects of the business from in-licensing and development to commercialization (including sales and marketing). He was the founding CEO of Prism Pharmaceuticals, a specialty pharmaceutical company that he led from inception to the sale of the company to Baxter International and a portfolio investment of Mr. Futch's prior firm. He holds degrees in physiology, medicine and surgery from The London Hospital (University of London) and is a Member of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom, and of the International Society of Hypertension.
Yichen Wang, M.D., Ph.D., is a Vice President at HCRx. Dr. Wang primarily supports HCRx's research efforts. Dr. Wang also participates in HCRx's business development and transaction-related activities, including financial analysis, transaction structuring and due diligence. Prior to joining HCRx, Dr. Wang was an experienced life science strategy consultant. Dr. Wang holds a Ph.D. in Molecular Biology and Genetics and an M.B.A from the University of Delaware. Dr. Wang is also a trained Ophthalmologist and obtained her M.D. from the Capital Medical University (Beijing, China).